aspen to raise bid from 55c to 65c? smh articl, page-41

Thanks...makes 50c look pretty good if its true.

I suspect Sigma are now in a position where they know they can walk away from Aspen and fix their balance sheet by selling several assets and this has Aspen over a barrel because their strategic partner GSK wants to see Herron out of the picture, or at least under their indirect influence and on top of that Aspen would want the Orphan suite and all the generics under license.

In other words it appears Sigma are now in the enviable position where they can pressure Aspen to move by having these other options and the obvious imperative to pull the trigger on something soon to pay down debt.